> Detailanzeige

Cattaneo, Chiara; Salmanton-García, Jon; Marchesi, Francesco; El-Ashwah, Shaimaa; Itri, Federico; Weinbergerová, Barbora; Gomes Da Silva, Maria; Dargenio, Michelina; Dávila-Valls, Julio; Martín-Pérez, Sonia; Farina, Francesca; Van Doesum, Jaap; Valković, Toni; Besson, Caroline; Poulsen, Christian Bjørn; López-García, Alberto; Žák, Pavel; Schönlein, Martin; Piukovics, Klára; Jaksic, Ozren; Cabirta, Alba; Ali, Natasha; Sili, Uluhan; Fracchiolla, Nicola; [...]

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
  • Beteiligte: Cattaneo, Chiara; Salmanton-García, Jon; Marchesi, Francesco; El-Ashwah, Shaimaa; Itri, Federico; Weinbergerová, Barbora; Gomes Da Silva, Maria; Dargenio, Michelina; Dávila-Valls, Julio; Martín-Pérez, Sonia; Farina, Francesca; Van Doesum, Jaap; Valković, Toni; Besson, Caroline; Poulsen, Christian Bjørn; López-García, Alberto; Žák, Pavel; Schönlein, Martin; Piukovics, Klára; Jaksic, Ozren; Cabirta, Alba; Ali, Natasha; Sili, Uluhan; Fracchiolla, Nicola; [...]
  • Erschienen: MDPI AG, 2022
  • Erschienen in: Cancers
  • Sprache: Englisch
  • DOI: 10.3390/cancers14225530
  • ISSN: 2072-6694
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p &lt; 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count &gt;500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.</jats:p>
  • Zugangsstatus: Freier Zugang